BR112015032800A2 - “processo para a produção de um anticorpo” - Google Patents

“processo para a produção de um anticorpo”

Info

Publication number
BR112015032800A2
BR112015032800A2 BR112015032800A BR112015032800A BR112015032800A2 BR 112015032800 A2 BR112015032800 A2 BR 112015032800A2 BR 112015032800 A BR112015032800 A BR 112015032800A BR 112015032800 A BR112015032800 A BR 112015032800A BR 112015032800 A2 BR112015032800 A2 BR 112015032800A2
Authority
BR
Brazil
Prior art keywords
antibody
production
provides
present
improved process
Prior art date
Application number
BR112015032800A
Other languages
English (en)
Portuguese (pt)
Inventor
Bandyopadhyay Sanjay
Patel Sanjay
Kumar Mendiratta Sanjeev
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of BR112015032800A2 publication Critical patent/BR112015032800A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112015032800A 2013-07-06 2014-07-07 “processo para a produção de um anticorpo” BR112015032800A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IN2014/000450 WO2015004679A1 (en) 2013-07-06 2014-07-07 Improved process for production of monoclonal antibodies
IN2285MU2013 IN2013MU02285A (enExample) 2013-07-06 2014-07-07

Publications (1)

Publication Number Publication Date
BR112015032800A2 true BR112015032800A2 (pt) 2017-07-25

Family

ID=51794933

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015032800A BR112015032800A2 (pt) 2013-07-06 2014-07-07 “processo para a produção de um anticorpo”

Country Status (18)

Country Link
US (1) US20160215319A1 (enExample)
EP (1) EP3019528A1 (enExample)
JP (1) JP2016526385A (enExample)
CN (1) CN105431454A (enExample)
AR (1) AR096839A1 (enExample)
AU (1) AU2014288811B2 (enExample)
BR (1) BR112015032800A2 (enExample)
CA (1) CA2917484A1 (enExample)
EA (1) EA201690171A1 (enExample)
HK (1) HK1218297A1 (enExample)
IL (1) IL243011A0 (enExample)
IN (1) IN2013MU02285A (enExample)
MX (1) MX2016000123A (enExample)
NZ (1) NZ715246A (enExample)
SG (1) SG11201510342VA (enExample)
TW (1) TW201514305A (enExample)
WO (1) WO2015004679A1 (enExample)
ZA (1) ZA201509334B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) * 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2017122157A1 (en) * 2016-01-14 2017-07-20 Dr. Reddy’S Laboratories Limited Cell culture process
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
JP2020188737A (ja) * 2019-05-23 2020-11-26 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体の製造方法
KR102682066B1 (ko) * 2021-10-12 2024-07-05 프레스티지바이오로직스 주식회사 항체 집단의 제조 방법
WO2025160161A1 (en) * 2024-01-23 2025-07-31 Amgen Inc. Methods for modulating monoclonal antibody charge variants

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
WO2002076578A1 (en) * 2001-03-27 2002-10-03 Smithkline Beecham Corporation Control of glycoforms in igg
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
WO2011019619A1 (en) * 2009-08-11 2011-02-17 Genentech, Inc. Production of proteins in glutamine-free cell culture media
US9045536B2 (en) * 2009-12-23 2015-06-02 Merck Sharp & Dohme Corp. Cell line 3M
WO2011085095A2 (en) * 2010-01-07 2011-07-14 Dr. Reddy's Laboratories Ltd. Enhanced protein expression
CA2795461C (en) * 2010-04-26 2018-04-24 Novartis Ag Improved cell cultivation process
MY163081A (en) * 2010-12-28 2017-08-15 Chugai Pharmaceutical Co Ltd Animal cell culturing method
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법

Also Published As

Publication number Publication date
HK1218297A1 (zh) 2017-02-10
JP2016526385A (ja) 2016-09-05
AU2014288811B2 (en) 2017-06-08
ZA201509334B (en) 2017-03-29
MX2016000123A (es) 2016-07-14
EA201690171A1 (ru) 2016-06-30
IL243011A0 (en) 2016-03-31
IN2013MU02285A (enExample) 2015-06-19
NZ715246A (en) 2017-07-28
CA2917484A1 (en) 2015-01-15
CN105431454A (zh) 2016-03-23
WO2015004679A1 (en) 2015-01-15
SG11201510342VA (en) 2016-01-28
US20160215319A1 (en) 2016-07-28
TW201514305A (zh) 2015-04-16
AU2014288811A1 (en) 2016-01-28
EP3019528A1 (en) 2016-05-18
AR096839A1 (es) 2016-02-03

Similar Documents

Publication Publication Date Title
AR096839A1 (es) Proceso mejorado para la producción de anticuerpos monoclonales
EA201992670A1 (ru) Способ получения биспецифических антител, биспецифические антитела и терапевтическое применение таких антител
BR112019007288A2 (pt) proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente
AR096713A1 (es) Proceso de purificación para anticuerpos monoclonales
ZA201703241B (en) Anti-c5 antibodies and methods of use
BR112016010706A2 (pt) anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, sequência de ácido nucleico, vetor de expressão, célula hospedeira e método de produção de um anticorpo
UY32501A (es) Anticuerpo antagonista específico para el heterodímero alfa4-beta7
EA201490815A1 (ru) Составы этанерцепта, стабилизированные с помощью аминокислот
EA201890028A1 (ru) Антитело, связывающее cd3 человека
CL2011002360A1 (es) Anticuerpo anti-alfa5beta1; molecula de acido nucleico que codifica el anticuerpo;celula huesped; metodo para produccionde anticuerpos anti-alfa5beta1; inmunoconjugado que comprende el anticuerpo; composicion farmaceutica.
BR112015017354A2 (pt) método para detectar pelo menos uma base modificada
BR112012026766A2 (pt) métodos in vitro para gerar uma proteína heterodimérica, para a seleção de um anticorpo biespecífico e para inibir o crescimento, vetor de expressão, célula hospedeira, proteína heterodimérica, composição farmacêutica.
AR106201A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
PH12018501282A1 (en) Anti-c5 antibodies and methods of use
BR112015027812A2 (pt) processo contínuo de multietapa para purificação de anticorpos
MX2011000011A (es) Anticuerpos estables y solubles que inhiben el vegf.
AR090017A1 (es) Agonistas de fgfr1 y sus metodos de uso
BR112015024553A2 (pt) anticorpo multiespecífico, anticorpo isolado, ácido nucleico isolado, célula hospedeira, método de produção de anticorpo, imunoconjugado, formulação farmacêutica, uso de anticorpo e método de tratamento de indivíduos com distúrbio
BR112015019341A2 (pt) Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal
AR087608A1 (es) Moleculas biespecificas de union a antigeno activadoras de celulas t
EA201590550A1 (ru) Композиции и способы получения гликопротеинов
BR112017006602A2 (pt) método de conjugação de um polipeptídeo
EA201990894A1 (ru) Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
AR095348A1 (es) Medios de cultivo celular y métodos de producción de anticuerpos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]